Strongyloides stercoralis infection in a DLBCL patient treated with rituximab and BTK inhibitor: A case report and literature review.

ABSTRACT:

Rationale

Diffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin's lymphoma characterized by high malignancy, rapid onset and aggressive clinical behavior. The disease exhibits considerable heterogeneity, which influences clinical and immunophenotypic characteristics, which in turn affect treatment outcomes and prognosis. Recently, targeted therapies have been introduced, offering improved therapeutic efficacy but with risks such as immunosuppression and opportunistic infections.

Patient concerns

We report a case of a patient diagnosed with DLBCL who experienced immunosuppression as a result of treatment with rituximab and a Bruton's tyrosine kinase inhibitor, which subsequently led to Strongyloides stercoralis infection.

Diagnoses

The patient was di

SUBMITTER: Liu W 

PROVIDER: S-EPMC11856888 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature